tradingkey.logo

Eli Lilly rises after oral pill helps maintain weight loss in late-stage trial

ReutersDec 18, 2025 2:52 PM

Shares of U.S. drugmaker Eli Lilly LLY.N up 3.3% at $1,072.44

Lilly says its oral pill, orforglipron, helps maintain weight loss in patients switching from injectable versions of GLP-1 drugs

In the late-stage trial, patients who took orforglipron for 52 weeks, after an initial treatment period of 72 weeks with Wegovy or Zepbound, showed superior weight maintenance compared to placebo

An oral weight-loss pill would help Lilly further widen its lead over Novo Nordisk NOVOb.CO

Up to last close, LLY up 35% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI